首页>
外文期刊>clinical drug investigation
>Brodimoprim in Upper Respiratory Tract InfectionsTwo Meta-Analyses of Randomised, Controlled Clinical Trials in Acute Sinusitis and Otitis Media
【24h】
Brodimoprim in Upper Respiratory Tract InfectionsTwo Meta-Analyses of Randomised, Controlled Clinical Trials in Acute Sinusitis and Otitis Media
展开▼
机译：Brodimoprim in Upper Respiratory Tract InfectionsTwo Meta-Analyses of Randomised, Controlled Clinical Trials in Acute Sinusitis and Otitis Media
Brodimoprim is a selective inhibitor of bacterial dihydrofolate reductase with a broad spectrum of antibacterial activity encompassing most common upper respiratory tract pathogens. The relative clinical efficacy of this agent was evaluated in 2 meta-analyses of randomised nonblind parallel-group studies of patients with upper respiratory tract infections. These analyses included 304 adults with acute sinusitis from 7 investigations and 594 children with acute otitis media from 14 investigations. Based on physician-rated global clinical efficacy in children with otitis media, brodimoprim showed superiority over ampicillin, erythromycin and cefalexin, and equivalence with amoxicillin and cefradine; pooled ratings again favoured brodimoprim. Global clinical efficacy among patients with sinusitis showed a slightly superior effect for brodimoprim over amoxicillin, and equivalence for brodimoprim and roxithromycin. No intergroup differences were apparent between brodimoprim and doxycycline or cefalexin in this setting, but small sample size precluded establishing equivalence. Pooled overall results, however, again (marginally) favoured brodimoprim. In both settings, brodimoprim was generally as well tolerated as any comparator agent, although better tolerated than ampicillin in patients with otitis media. These results demonstrate that brodimoprim is a worthwhile choice in the treatment of children with otitis media and adults with sinusitis.
展开▼
